← Leaderboards
Anthony D Saleh
Mirecule, Inc.
$6,384,273
Attributed
$6,884,273
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2020–25$2.5M$1.9M$1.3M$625K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,884,273 · 3
By mechanism
R44$4,884,273 · 2
U44$2,000,000 · 1
Top collaborators
- Robert F Place1 shared
Others in their field
Other Emerging Leaders on “Small Business Innovation Research Grant”
- Gary Fanger · Rise Therapeutics, Llc$23,463,293
- Molly Wasko · University Of Alabama At Birmingham$18,764,568
- Ashkan Vaziri · Biosensics, Llc$17,149,241
- Bryan L McLaughlin · Micro-Leads, Inc.$11,109,320
- Federico Cividini · Cardiac Rsk3 Inhibitors, Llc$10,485,488
- Matthew Golden · Maphabit, Inc.$8,701,960
Research focus
Small Business Innovation Research GrantMouse ModelIn VivoEffective TherapyScale UpDoseToxic EffectMaximum Tolerated DoseInnovationToxicologyOligonucleotidesPharmacokinetics And PharmacodynamicsSafetyRattusChemistryBiodistributionAntibodiesLegal PatentGenesBindingHalf-LifeBloodCytokineCells
Grant awards (8)
A Novel RNA Therapeutics Platform to Treat Facioscapulohumeral Muscular Dystrophy and other Neuromuscular Disorders$1,225,173
R44 · FY2025 · NS · contact PI
Development of an antibody-oligonucleotide conjugate for treatment of Head and Neck Squamous Cell Carcinoma$896,878
R44 · FY2025 · CA · contact PI
A Novel RNA Therapeutics Platform to Treat Facioscapulohumeral Muscular Dystrophy and other Neuromuscular Disorders$1,159,302
R44 · FY2024 · NS · contact PI
Development of an antibody-oligonucleotide conjugate for treatment of Head and Neck Squamous Cell Carcinoma$863,708
R44 · FY2024 · CA · contact PI
A Novel RNA Therapeutics Platform to Treat Facioscapulohumeral Muscular Dystrophy and other Neuromuscular Disorders$368,681
R44 · FY2022 · NS · contact PI
Novel Targeted Nanomedicine Delivering MicroRNA-30-5p ReplacementTherapy for Multi-drug Resistant Cancer Treatment$1,000,000
U44 · FY2021 · CA · contact PI
A Novel RNA Therapeutics Platform to Treat Facioscapulohumeral Muscular Dystrophy and other Neuromuscular Disorders$370,531
R44 · FY2021 · NS · contact PI
Novel Targeted Nanomedicine Delivering MicroRNA-30-5p ReplacementTherapy for Multi-drug Resistant Cancer Treatment$1,000,000
U44 · FY2020 · CA